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Background. Various biomarkers and assays have been used for assessment of (anti)oxidant status in hemodialysis patients,
including those intended for measurement of serum total (anti)oxidants, most often as a part of panel biomarkers.Methods. Serum
(anti)oxidant statuswasmeasured in 32 chronically hemodialyzed patients and in 47 healthy persons, using twooxidations and three
antioxidant assays. Results. The patients before the hemodialysis session have had higher values of total oxidants in comparison to
the healthy persons, with a further increase during the hemodialysis. These findings were confirmed with both oxidation assays,
but they differ in the percentage of increase and the statistical significance. All three antioxidant assays showed significantly higher
values of the total serum antioxidants in the patients before the hemodialysis session in comparison to the healthy persons, and their
significant decrease during the hemodialysis. However, the assays differ in the percentage of decrease, its statistical significance, and
the correlations with uric acid.Conclusion.The variability of results of total (anti)oxidants which are obtained using different assays
should be taken into account when interpreting data from clinical studies of oxidative stress, especially in complex pathologies such
as chronic hemodialysis.
1. Introduction
Oxidative stress, as a state of substantial prooxidant imbal-
ance between oxidants and antioxidants within the cells and
tissues, leads to an oxidative damage of proteins, lipids, and
DNA. As such, the oxidative stress implies numerous non-
communicable diseases, including end-stage renal disease [1].
Accumulation of uremic toxins [2], bioincompatibility of the
dialyzer’s membrane [3], depletion of low molecular antioxi-
dants, in the first place ascorbic acid, during the hemodialysis
session [4], and excessive and indiscriminate use of intra-
venous iron preparations [5] have been described as the
main factors which cause oxidative stress in the chronically
hemodialyzed patients. There is a large body of evidence that
the prooxidant state of the chronically hemodialyzed patients
is associated with cardiovascular disease [6–8], renal anemia
[9, 10], and mineral and bone disorders [11], which largely
contribute to their increased morbidity and mortality.
Although the oxidative stress in chronically hemodi-
alyzed patients has been extensively studied, there is no
consensus about the use of (anti)oxidant status biomarkers
and assays.Thus, different biomarkers and assays and various
combinations of them have been used in different clinical
studies. Among others, the assays formeasurement of the lev-
els of total oxidants [12] and total antioxidants [13] in serum/
plasma have been used inmany studies. However, using these
assays, sometimes different [14, 15] or even opposite findings
are reported [16, 17], especially for the total serum antiox-
idants. These inconsistent data in the literature could be a
result of many factors like variations in the process of
hemodialysis itself and/or influence of the analytical factors,
that is, the methods used.
Therefore, the aim of this study was to conduct a com-
parative analysis of some of the assays for quantification of
the total oxidants and the total antioxidants in serum samples
from chronically hemodialyzed patients both before and after
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the single hemodialysis session and in a group of healthy
persons.More specifically, we have evaluated two commercial
assays for determining the serum oxidants, as well as two
commercial assays and one in-house assay for measurement
of total serum antioxidants. We focused primarily on com-
mercial assays because of the less variability in preparation
of reagents and standards, which enables generation of more
accurate and precise results.
2. Materials and Methods
2.1. Samples. Serum samples from 32 chronically hemodia-
lyzed patients and 47 healthy persons were analyzed in this
study.
The samples from the chronically hemodialyzed patients
who were on hemodialysis treatment for more than 1 year
and who were treated with a protocol of three hemodialysis
sessions a week were obtained from the Department of
Hemodialysis at Military Hospital in Skopje. The mean age
of the patients was 61 ± 10 years (range 38–78 years). Blood
for analysis was drawn immediately before and after the
second hemodialysis session within the week in blood col-
lecting tubes (Sarstedt) containing clot activator. Before the
hemodialysis blood was drawn after an overnight fasting.The
serum was separated with standard centrifugation procedure
and immediately divided in portions which were kept tightly
closed at −70∘C until analysis [18].
The results obtained from the hemodialyzed patientswere
compared to those from 47 healthy persons (mean age: 25±3
years), candidates for military service. They were physically
and mentally healthy, without any chronic or acute disease,
as confirmed with their clinical presentation at the day of
blood sampling and the results from the standard medical
examinations. They did not report use of any antioxidants
and supplements. Fasting blood samples, drawn at about
9:00–9:30 am, were obtained during the scheduled standard
systematicmedical examination. After the centrifugation, the
sera were aliquoted in portionswhichwere kept tightly closed
at −70∘C until analysis.
The Command of the Military Medical Center in Skopje
approved this study, as stated in the document N number
07-1756/1 from the Army mail 2990/80, Army of Republic of
Macedonia.
2.2. Assays. Within this study the following assays have
been evaluated: the reactive oxygen metabolites (ROM), test
kit d-ROM from Diacron [19] (Grosseto, Italy); the total
oxidant status (TOS), test kit fromRel Assay Diagnostics [20]
(Gaziantep, Turkey); the ferric reducing ability of plasma
(FRAP), an in-house assay; the total antioxidant status (TAS),
test kit from Rel Assay Diagnostics; and the biological
antioxidant potential (BAP), test kit from Diacron. We have
also measured the serum concentrations of uric acid using
the method with uricase, with a dedicated test kit, on the
autoanalyzer LX20-Pro (Beckman-Coulter).
2.2.1. Oxidation Assays. The d-ROM assay is intended for
measurement of the concentration of total hydroperoxides
in serum or heparin plasma. The method was first described
by Alberti et al. in 2000 [21]. It is based on the following
principle. In vitro, in an acidic buffered solution (pH = 4.8),
the iron ions are released from the serum (plasma) proteins
and catalyze the reaction of transformation of hydroperox-
ides into alkoxyl and peroxyl radicals, which further react
with the chromogen N,N-diethyl-p-phenylenediamine. The
concentration of the colored complex is directly proportional
to the concentration of the hydroperoxides which are present
in the sample.The absorbance is measured at 505 nm, and the
results are expressed in CARR U. One CARR U corresponds
to 0.08mg/100mL H
2
O
2
. The characteristics of the assay
were evaluated and validated by Verde et al. in 2002 [22],
who report that the assay is reliable even in patients with
hyposideremic anemia. In our study the assay has been auto-
mated on the autoanalyzer LX20-Pro (Beckman-Coulter).
TheTOS assay, developed by Erel in 2005 [23], is intended
for measurement of the level of oxidant molecules in various
biological samples. The assay is based on the principle of
oxidation of the ferrous ion-chelator complex to ferric ion
with the oxidants which are present in the sample. The ferric
ion further forms a colored complex with a chromogen, and
the color intensity is directly proportional to the level of
total oxidants. The absorbance is measured at 530 nm. The
assay is calibrated with hydrogen peroxide and the results are
expressed in 𝜇mol H
2
O
2
Eq/L. We have performed this assay
in microtiter plates.
2.2.2. Antioxidant Assays. The FRAP, TAS, and BAP assays
are intended for direct measurement of the total antioxidant
activity of the sample.
The in-house FRAP assay is a modification of the original
method of Benzie and Strain [24].Themethod is based on the
principle of reduction of the ferric-tripyridyltriazine complex
to the ferrous formwith the antioxidants which are present in
the sample.The increase of absorbance ismeasured at 593 nm,
in a kinetic mode. In a modified method we have used an
end-point approachwith incubation of exactly 8minutes.The
absorbance has been measured at 600 nm on a microplate
autoanalyzer ChemWell [25]. A freshly prepared standard
solution of FeSO
4
has been used for calibration of the assay.
The results are expressed in 𝜇mol/L FeSO
4
.
The TAS assay, developed by Erel in 2004 [26], is based on
the principle of reduction of the dark blue-green colored 2,2󸀠-
azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS)
radical to its colorless reduced form with the antioxidants
which are present in the sample.The change of the absorbance
is measured at 660 nm. The assay is calibrated with a stable
antioxidant standard solution, vitamin E analog—Trolox
Equivalent.The results are expressed in 𝜇mol/L (𝜇mol Trolox
Equivalent/L). We have automated this assay on the autoana-
lyzer LX20-Pro (Beckman-Coulter).
The BAP assay is based on the ability of a colored solution
which contains ferric ions bound to a chromogenic substrate
(a thiocyanate derived compound) to decolor upon reduction
of ferric to ferrous ions. The absorbance is measured at
505 nm, and the results are expressed as 𝜇Eq/L (𝜇Eq ferric
ions reducing antioxidants/L). Notably, there is no scientific
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paper which describes validation and verification of the
characteristics of this assay.This information is available from
themanufacturer of the reagent kit [27]. In our study the assay
was automated on the autoanalyzer LX20-Pro (Beckman-
Coulter).
All analyses have been run within one analytical series.
2.3. Statistical Analysis. The results from measurements are
expressed as mean ± standard deviation. The distribution of
the data was assessed with Kolmogorov-Smirnov test, using
Statistica 7 software.
The data which are normally distributed were processed
withMicrosoft Excel software.The statistical significance was
calculated with Student’s 𝑡-test (paired, two-sample equal
variance or two-sample unequal variance, as appropriate).
For the data which are not normally distributed, the
Wilcoxon matched pairs test or the Mann-Whitney 𝑈 test
was used, as appropriate (Statistica 7 software).
The difference between means was considered as statisti-
cally significant when it was 𝑃 < 0.05.
The statistical significance of the coefficients of correla-
tion was assessed according to the number of subjects within
the group, using a statistical table [28].
3. Results
3.1. Oxidation Assays. The results from both of the oxidation
assays (d-ROM and TOS) show an increase of the concentra-
tion of serum oxidants as a result of the single hemodialysis
session.However, there is a difference between the assayswith
regard to the percentage and the statistical significance of
the increase. More precisely, we have measured serum ROM
concentrations of 428 ± 120 CARR U before and 463 ± 120
CARR U immediately after the hemodialysis session, which
is a statistically significant increase for 8.2% (𝑃 < 0.025). In
contrast, as measured with the TOS assay, the percentage of
the increase has beenmuch higher (22.4%), but the difference
between the values obtained before (2.46 ± 1.86 𝜇mol H
2
O
2
Eq/L) and after (3.01 ± 2.38 𝜇mol H
2
O
2
Eq/L) the single
hemodialysis session was not statistically significant (𝑃 >
0.05). Coefficients of correlation between d-ROM and TOS
before and after the single hemodialysis session were −0.083
and 0.160, respectively (𝑃 > 0.05 for both comparisons).
We have also compared the results for serum oxidants
of the patients on hemodialysis and the healthy persons and
obtained consistent conclusions.
Namely, both ROM (408 ± 92 CARR U) and TOS (2.01 ±
0.81 𝜇mol H
2
O
2
Eq/L) levels were lower in the healthy per-
sons in comparison to the patients before the hemodialysis
session, but the differences were not statistically significant
(𝑃 > 0.05 for both comparisons). However, the increased
values of ROM and TOS after the single hemodialysis session
were significantly different from those measured in the
healthy persons (𝑃 = 0.023 for ROM; 𝑃 = 0.029 for TOS).
The results from the oxidation assays are presented in
Figure 1. For better visual presentation the results of the TOS
assay are multiplied by 100.
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Figure 1: Serum oxidants in patients on chronic hemodialysis and
healthy persons. ∗Statistically significant difference between patients
before and after the single hemodialysis session. ∗∗∗Statistically sig-
nificant difference between patients after hemodialysis and healthy
persons.
3.2. Antioxidant Assays. Before the hemodialysis session,
very high values of FRAP in the patients (1758±320 𝜇mol/L),
compared to the healthy persons (1378 ± 159 𝜇mol/L), were
measured and this difference was highly statistically signifi-
cant (𝑃 < 0.001). However, measured immediately after the
hemodialysis, the values of FRAP significantly dropped to
1080±162 𝜇mol/L, or on average, for 38.6%, which was again
highly statistically significant in comparison to the values
before the hemodialysis and to those of the healthy persons
(𝑃 < 0.001 for both comparisons).
Similarly, TAS significantly decreased from 2300 ±
380 𝜇mol/L before the hemodialysis to 1490 ± 240 𝜇mol/L
after the hemodialysis session (𝑃 < 0.001). The percentage
of the decrease of TAS (35.2%) was almost identical to that
of the FRAP assay. The group of healthy persons have had
TAS values of 1550 ± 150 𝜇mol/L, which were significantly
lower than those measured in the hemodialyzed patients
before the hemodialysis (𝑃 < 0.001). However, the decline
of the TAS values during the hemodialysis session was
not so pronounced as to reach a statistical significance in
comparison to the healthy persons.
General conclusions which are withdrawn from the BAP
assay are the same as those of the FRAP assay. Exceptions
are the percentage of the BAP decrease as a result of
the single hemodialysis session and the levels of statistical
significance of the differences between the healthy subjects
and the hemodialysis patients both before and after the single
hemodialysis session. More precisely, in the hemodialyzed
patients we have measured 2592 ± 239 𝜇Eq/L of BAP before
and 2265 ± 268 𝜇Eq/L after the hemodialysis (𝑃 < 0.001),
which is a decrease for only 12.6%. BAP values of the
healthy persons were 2442±149 𝜇Eq/L and were significantly
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Table 1: Coefficients of correlation between FRAP, TAS, and BAP
assays, both before and after the single hemodialysis session.
TAS BAP
Before HD After HD Before HD After HD
FRAP Before HD 0.903
∗∗ 0.527∗∗
After HD 0.805∗∗ 0.259ns
TAS Before HD 0.575
∗∗
After HD 0.668∗∗
nsNonsignificant.
∗∗
𝑃 < 0.01.
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Figure 2: Serum antioxidants in patients on chronic hemodialysis
and healthy persons. ∗Statistically significant difference between
patients before and after the single hemodialysis session. ∗∗Statis-
tically significant difference between patients before hemodialysis
and healthy persons. ∗∗∗Statistically significant difference between
patients after hemodialysis and healthy persons.
different from the values of hemodialyzed patients before and
after the hemodialysis (𝑃 < 0.01 for both comparisons).
The graphic presentation of the results obtained from the
antioxidant assays is given in Figure 2. The coefficients of
correlation between these assays, both before and after the
single hemodialysis session, are given in Table 1.
The serum concentrations of uric acid in the hemodi-
alyzed patients before the hemodialysis session (320 ±
62 𝜇mol/L) were not significantly different from those mea-
sured in the healthy persons (303 ± 56 𝜇mol/L), 𝑃 > 0.05.
However, during the hemodialysis session, the serum uric
acid concentrations decreased to 84 ± 30 𝜇mol/L, which
is, on average, a decrease for 73.8%, and which is highly
statistically significant in comparison to the values before the
hemodialysis and to those of the healthy persons (𝑃 < 0.001
for both comparisons).
Moreover, the serumuric acid concentrations significant-
ly correlated with FRAP, TAS, and BAP in the hemodialyzed
Table 2: Correlation coefficients of uric acid versus FRAP, TAS, and
BAP.
Correlation
coefficients
Before
hemodialysis
After
hemodialysis Healthy persons
Uric acid
versus FRAP 0.547
∗∗ 0.430∗ 0.875∗∗
Uric acid
versus TAS 0.662
∗∗ 0.521∗∗ 0.930∗∗
Uric acid
versus BAP 0.410
∗ 0.385∗ 0.366∗
∗
𝑃 < 0.05.
∗∗
𝑃 < 0.01.
patients, both before and after the hemodialysis session, as
well as in the healthy persons (results shown in Table 2).
4. Discussion
4.1. Oxidation Assays. Two assays, for measurement of the
serum oxidants (d-ROM and TOS), were evaluated in this
study. These assays are based on completely different prin-
ciples. Therefore, it was not surprising that the coefficients
of correlation between them, both before and after the single
hemodialysis session, were not statistically significant. How-
ever, the analysis of the results demonstrated that the con-
clusions which are withdrawn from both assays are generally
consistent, yet with some differences.
It has been shown with both of the oxidation assays
that before the hemodialysis session the patients had higher
concentrations of serum oxidants than the healthy persons,
but the difference was not statistically significant.
In other clinical studies, using the d-ROM assay [14,
29], higher values of serum oxidants were also found in
hemodialyzed patients in comparison to healthy persons.
Notably, in both studies the difference between the patients
and the healthy persons was statistically significant, but the 𝑃
values were above 0.025, indicating small differences between
the groups. However, in another study [30] the difference of
the ROM concentrations between hemodialyzed patients and
healthy persons was more pronounced.
It has been also shown with both of the oxidation assays
that there was an increase in the concentrations of serum
oxidants during the hemodialysis session, leading to a sta-
tistically significant difference between the hemodialyzed
patients and the healthy subjects.
Others, using the d-ROM assay, have also found a signif-
icant increase of ROM levels during the single hemodialysis
session [14], but there is also a different finding [15].
To the best of our knowledge, the levels of serum oxidants
in hemodialyzed patients have not beenmeasured beforewith
the TOS assay from Rel Assay Diagnostics.
Altogether, although not specific for a particular oxidant
or oxidation mechanism and based on completely different
principles, the d-ROM and TOS assays in this study con-
sistently reflected the oxidation state of the hemodialyzed
patients, which are slightly increased oxidation in compari-
son to the healthy subjects and further increase during the
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Table 3: Relative contributions of individual plasma antioxidants to
total FRAP and TAS values (data from literature).
Estimated %
contribution to total
FRAP
Estimated %
contribution to total
TAS
Uric acid 60 33
Protein 10 53
Bilirubin 5 2
Ascorbic acid 15 5
𝛼-Tocopherol 5 2
Others 5 5
single hemodialysis session. However, assessing the increase
of serum oxidants during the single hemodialysis session,
we found an inconsistence between these two assays with
regard to the percentage of the increase and its statistical
significance, which warrants caution in the interpretation of
the results.
4.2. AntioxidantAssays. After the introduction of the concept
of oxidative stress as an imbalance between the molecules
with prooxidant and antioxidant activity, a number of meth-
ods for measurement of total nonenzymatic plasma antioxi-
dant activity have been published. There is almost no disease
or condition where the total nonenzymatic plasma antioxi-
dant activity has not been assessed. However, the intention
to relate directly the levels of total antioxidants in food with
the total plasma antioxidant activity is not justified because
of the known ADME (absorption, distribution, metabolism,
and elimination) effects of the human body on the nutritional
antioxidants [31]. In addition, it is also not justifiable to relate
the values of the total plasma antioxidant activity, directly
and in an indiscriminate manner, with the state of good
health. The chronically hemodialyzed patients are such an
example. Still, the total antioxidant assays remain a useful
tool for oxidative stress research, in carefully designed clinical
studies, as members of panel biomarkers and always in
correlation with other clinical data.
Three photometric assays for direct measurement of
the total antioxidant activity (FRAP, TAS, and BAP) have
been evaluated in this study, all of them based on different
principles. Namely, the FRAP and BAP assays are based on
the principle of reduction of ferric to ferrous ions but with
use of different complexes, while the TAS assay is based
on the principle of reduction of ABTS radical. All three
assays are nonspecific and are intended for measurement of
various antioxidants which are present in the sample. Relative
contributions of the most common plasma antioxidants to
the values of FRAP [24] and TAS [26] are given in Table 3.
The manufacturer does not provide such data for the BAP
assay, but referring to the FRAP assay which also uses the
principle of reduction of ferric ions presents data from
experiments with uric acid, bilirubin, ascorbic acid, and 𝛼-
tocopherol [27]. Since hyperbilirubinemia is not an issue in
the patients included in this study (data not shown) and
proteins are nondialyzable molecules, we focus on uric acid
and its correlations with the total antioxidant status assays,
both before and after a single hemodialysis session.
When the FRAP, TAS, and BAP assays were applied
on the same sets of serum samples from hemodialyzed
patients and healthy subjects, the results generally reflected
the same trends, although there were also some differences.
In addition, all three assays correlated significantly with each
other both before and after the single hemodialysis session,
with exception of the correlation between the FRAP and BAP
assays after the hemodialysis session.
Before the hemodialysis session the patients had signifi-
cantly higher levels of total antioxidants in comparison to the
healthy persons, which has been demonstrated with all three
assays.
This, at a first glance paradoxical finding, is in accordance
with the results fromother studies where the total antioxidant
status was measured with the FRAP assay [32, 33]. However,
there are also some opposite findings [34]. To the best of
our knowledge, the BAP assay from Diacron has not been
used before for a parallelmeasurement of total antioxidants in
hemodialyzed patients and healthy persons. There is also no
information that the TAS assay from Rel Assay Diagnostics
had been applied on serum samples from hemodialyzed
patients. However, an assay based on the ABTS reduction
principle has been used before [35] and the authors report
higher levels of total antioxidants in chronically hemodia-
lyzed patients in comparison to healthy persons.
The high levels of total serum antioxidants in the hemodi-
alyzed patients before the single hemodialysis session have
been attributed to the abundance of small molecules with
reductive properties, mostly the uric acid [36, 37]. How-
ever, we did not find that the slightly higher serum uric
acid concentrations of the patients before the hemodialysis
session were significantly different from those measured in
the healthy subjects. As such, it appears that the uric acid
is not a primary cause of the remarkably high levels of
total antioxidants in the predialyzed patients and that other
molecules with ability to reduce the ferric ions or the ABTS
radicals substantially contribute to their levels.
In contrast to our (and others’) results, there are also
findings of lower levels of total serum antioxidants in chron-
ically hemodialyzed patients before the hemodialysis session
in comparison to healthy subjects [38, 39]. Notably, in these
clinical studies were used completely different methods (in
which hydroxyl radical is generated) than those evaluated in
our study [40, 41].
All three antioxidant assays have shown that there was
a highly significant decrease of the content of total serum
antioxidants during the single hemodialysis session.
This is a common finding of many clinical studies [15,
42] which is explained with depletion of the low molecular
antioxidants through the dialyzer’s membrane. However,
there are also some opposite findings [43].
The percentage of decrease of the levels of antioxidants
during the hemodialysis session was rather high and almost
identical when measured with the FRAP and TAS assays
(38.6% and 35.2%, resp.) but almost three times lower when
measured with the BAP assay (12.6%). This finding could
possibly be explained with the fact that the coefficient of
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correlation between the BAP and the uric acid is the lowest in
comparison to all other coefficients of correlation of the uric
acid (Table 2). In addition, the lowest correlation between
BAP and uric acid could mean that the BAP assay reflects
better the presence of antioxidants other than the uric acid,
with possible beneficial health effects. In this context, a recent
study demonstrated that hemodialysis patients with higher
BAP values have better survival rate [44].
Serum total antioxidants were lower in the postdialyzed
patients than in the healthy subjects, which has been demon-
strated by all three assays.
This difference was statistically significant for the FRAP
and BAP assays only (iron reduction principle) but not
for TAS assay (ABTS reduction principle). Once more this
finding emphasizes the influence of different assays on the
final conclusions which are withdrawn for the same sets of
clinical samples.
5. Conclusion
Conducting this comparative analysis of some of the total
(anti)oxidant assays, using the same sets of serum samples
from chronically hemodialyzed patients and healthy subjects,
we demonstrate that even with a tight control of all preanalyt-
ical and analytical variables (such as identical treatment of all
samples, automation ofmost of the assays, and analysiswithin
the same analytical series), different assays intended for
measurement of the same complex “analyte,” being the total
(anti)oxidants, occasionally lead to different conclusions.
However, we did not get any opposite results. Discussing
our findings, we highlight data from the literature about
the levels of total (anti)oxidants in chronically hemodialyzed
patients that are sometimes inconsistent and even opposite,
which warrants careful evaluation of the results obtained
from laboratory measurements.
It is noteworthy that all assays which are evaluated in
this study, and many similar ones, are not specific for a par-
ticular (anti)oxidant. Besides, they have been used in many
clinical studies, individually or more often as a part of panel
biomarkers, and together with other clinical findings, thus
contributing to get a more complete insight of the changes of
the (anti)oxidant status as a result of a specific treatment or
condition. Therefore, the variability of measurements should
be taken into account in interpretation of data from clinical
trials. This study highlights the importance of this issue in
hemodialysis patients.
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